AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01263769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Starting dose: 5 mg by mouth twice each day for 12 weeks.
Study NCT02052778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle
Study NCT00790816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib monotherapy
Study NCT03748823 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ravulizumab OBDS
Description: The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.
Study NCT03748823 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ravulizumab OBDS
Description: The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.
Study NCT03748823 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ravulizumab
Description: Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
Study NCT03748823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
Study NCT03567733 — intervention group
Intervention type: DEVICE
Intervention: XIENCE Sierra
Description: Percutaneous coronary intervention
Study NCT06312150 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of peripheral blood (control group)
Description: Peripheral blood sample will be acquired in excess to the last scheduled control sample according to clinical practice.
Study NCT06312150 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of biological sample (Substudy-solid neoplasms)
Description: peripheral blood sample, bone marrow aspirate and fresh or paraffin biopsia tissutale will be collected for the substudy
Study NCT06312150 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of biological sample (substudy-leukaemia patients)
Description: sample of peripheral blood and bone marrow blood for the substudy, derived from paediatric or young adult leukaemia patients
Study NCT00790816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Description: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Study NCT03228602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recording of GEP (Gustatory Evoked Potentials)
Description: record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.
Study NCT03228602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of GEP (Gustatory Evoked Potentials)
Description: record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.
Study NCT04639388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological testing, questionnaires and experimental tasks
Description: Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition
Study NCT04639388 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological testing, questionnaires and experimental tasks
Description: Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition
Study NCT02689518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal aflibercept injection
Description: Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
Study NCT03324191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be matched for flavour, odour, and colour, to a tea beverage, without any active ingredient (tea extract).
Study NCT03324191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea beverage
Description: Tea beverage
Study NCT03324191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea extract (medium concentration)
Description: Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a medium concentration of tea extract.
Study NCT03324191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea extract (high concentration)
Description: Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a high concentration of tea extract.
Study NCT03324191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High fat liquid meal challenge
Description: A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids.
Study NCT03324191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat liquid meal challenge
Description: A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids.
Study NCT03541083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: prephase and consolidation (I and II)
Study NCT03501082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L Reuteri PB-W1 Strain
Description: L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
Study NCT03501082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L. Reuteri DSM20016T Strain
Description: L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
Study NCT03501082 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions
Study NCT03501082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Industrialized-Type Diet
Description: Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.
Study NCT03501082 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Industrialized-Type Diet
Description: Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.
Study NCT04135807 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microdevice
Description: Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus) released by the microdevice reservoirs. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas.
Study NCT01095549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WSTM TY101 FIR emitter (Far infrared therapy)
Description: A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on each HD section for a year.
Study NCT01095549 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo device
Description: A device without far infrared therapy
Study NCT04242355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
Study NCT04242355 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
Study NCT02943174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND programme for cancer patients
Description: Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual
Study NCT02943174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Standard personalized treatment of cancer
Study NCT02943174 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual (TAU)
Description: Standard personalized treatment of cancer
Study NCT02133495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Cadaveric Human Acellular Dermal Tissue
Study NCT00868634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
Study NCT00868634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
Study NCT00868634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
Study NCT00868634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
Study NCT00868634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
Study NCT00672698 — intervention group
Intervention type: PROCEDURE
Intervention: SURGERY
Description: ELECTIVE SURGICAL PROCEDURES
Study NCT03403803 — intervention group
Intervention type: DEVICE
Intervention: Optune
Description: Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located.~TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.
Study NCT01998256 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AV optimization
Description: Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
Study NCT01998256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV optimization
Description: Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
Study NCT05976360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab (SAR231893)
Description: Injection solution, subcutaneous
Study NCT05976360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab (SAR231893)
Description: Injection solution, subcutaneous.
Study NCT03071120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Mediated Intervention
Description: Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
Study NCT03743272 — intervention group
Intervention type: DEVICE
Intervention: LiverMultiScan
Description: Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
Study NCT04325672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers >1:64.
Study NCT01761916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLONIDINE
Description: Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
Study NCT01761916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPTOPRIL
Description: Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
Study NCT01691534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207 (J)
Description: TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14
Study NCT01691534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824 (PA)
Description: PA-824 200mg Days 1-14
Study NCT01691534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide (Z)
Description: 1500mg Days 1-14 Dosed by Weight
Study NCT01691534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofazimine (C)
Description: clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
Study NCT01691534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour
Description: Rifafour e-275 mg dosed by weight
Study NCT04686474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azadirachta indica leaves extract containing ointment intervention.
Description: Azadirachta indica leaves extract containing ointment, white petroleum, bee wax, stearyl alcohol
Study NCT02211560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine
Study NCT02211560 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03668873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Parent Training
Description: SPT provides a comprehensive intervention that teaches parents the basic concepts and practical skills to address an array of sleep problems.
Study NCT03668873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Parent Education
Description: SPE is a structured program intended to mimic treatment as usual. Thus, SPE is an accepted treatment and serves as an active comparator that controls for time and attention.
Study NCT01514799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric bypass
Description: two techniques of gastric bypass for studying the effects of making a long BP-limb
Study NCT01514799 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: two techniques of gastric bypass for studying the effects of making a long BP-limb
Study NCT01855529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine in one arm and placebo (NaCl) in the other arm
Study NCT01855529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine in one arm and placebo (NaCl) in the other arm
Study NCT00541372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin injection needle size
Description: The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
Study NCT00541372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: insulin injection needle size
Description: The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
Study NCT02453620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT02453620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: Undergo blood sample collection
Study NCT02453620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT02453620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT02453620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study NCT02453620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02453620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02453620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT02453620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02453620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT01614249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soybean oil soft gels
Description: Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
Study NCT01614249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil omega-3 EPA-rich soft gels
Description: A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
Study NCT01282034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marrow stimulation - Drilling or Microfractures
Description: Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.~Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective.
Study NCT01282034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MaioRegen Surgery
Description: MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.
Study NCT01239199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure of the exhaled NO
Description: The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
Study NCT02265458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical intervention and sensory isolation
Description: 30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
Study NCT02265458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Musical intervention and sensory isolation
Description: 30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
Study NCT03896438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
Study NCT03896438 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.